BioSpace News Archive

Opthea Limited, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that new data from the Phase 1b/2a clinical study of OPT-302 in patients with treatment refractory diabetic macular edema has been presented at the 2020 American Society of Retina Specialists Virtual Annual Meeting.

Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and provide a business update after market close on Thursday, August 6, 2020.

CorVel Corporation, a national provider of risk management solutions, is leveraging its experience and technology to provide clients with liability management services and monitor emerging legislation as claims related to COVID-19 increase.

Dr. Reddy’s Laboratories Ltd. announced approval of XEGLYZE lotion, 0.74%, a 505 NDA by the U.S. Food and Drug Administration. The approval triggers the contractual pre-commercialization milestone of $20 million payable to Hatchtech Pty Ltd.

Thompson Street Capital Partners announced that it has completed the sale of Analytical Lab Group, an industry-leading microbiology and viral lab, to Element Materials Technology, one of the world’s largest providers of materials and product qualification testing, inspection and certification services to the global aerospace, transportation & industrials, connected technologies, energy, and fire & building products sectors.

DURHAM, NC / ACCESSWIRE / July 27, 2020 / Heat Biologics, Inc. (“Heat”) (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine product candidate, today announced that on July 24, 2020, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, Inc. (“Nasdaq”), confirming that

Clearside Biomedical, Inc. announced that multiple posters and oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space were delivered at the American Society of Retina Specialists 2020 Virtual Annual Meeting.

Mateon Therapeutics announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc..

VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study

Progressive Care Inc. is pleased to announce operational performance data for June 2020, along with preliminary fiscal Q2 performance data, both of which demonstrate a continued robust trend of growth in sales, prescriptions, 340B income, and COVID- 19 testing service revenues.